Cargando…

Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling

BACKGROUND AND PURPOSE: CX‐5461 is a novel selective RNA polymerase I (Pol I) inhibitor. Previously, we found that CX‐5461 could inhibit pathological arterial remodelling caused by angioplasty and transplantation. In the present study, we explored the pharmacological effects of CX‐5461 on experiment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xia, Feng, Hua, Dai, Chaochao, Lu, Weida, Zhang, Jun, Guo, Xiaosun, Yin, Qihui, Wang, Jianli, Cui, Xiaopei, Jiang, Fan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328314/ https://www.ncbi.nlm.nih.gov/pubmed/33486761 http://dx.doi.org/10.1111/bph.15385

Ejemplares similares

A transcriptional program associated with cell cycle regulation predominates in the anti-inflammatory effects of CX-5461 in macrophage
por: Wang, Jie, et al.
Publicado: (2022)

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma
por: Kang, Chang-Won, et al.
Publicado: (2022)

CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I
por: Lehman, Stacey L., et al.
Publicado: (2022)

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
por: Quin, Jaclyn, et al.
Publicado: (2016)

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461
por: Son, Jinbae, et al.
Publicado: (2020)

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer
por: Cornelison, Robert, et al.
Publicado: (2021)

The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers
por: Ismael, Mohammed, et al.
Publicado: (2019)

Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461
por: Li, Guihong, et al.
Publicado: (2018)

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
por: El Hassouni, Btissame, et al.
Publicado: (2019)

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
por: Xuan, Jiachen, et al.
Publicado: (2020)

Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461
por: Masud, Tehmina, et al.
Publicado: (2021)

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
por: Sanij, Elaine, et al.
Publicado: (2020)

The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability
por: Mars, Jean-Clément, et al.
Publicado: (2020)

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
por: Xu, Hong, et al.
Publicado: (2017)

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
por: Pan, Min, et al.
Publicado: (2021)

CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma
por: Li, Leiming, et al.
Publicado: (2016)

Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension
por: Leopold, Jane A., et al.
Publicado: (2016)

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response
por: Snyers, Luc, et al.
Publicado: (2022)

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
por: Yan, Shunfei, et al.
Publicado: (2020)

Nucleolar stress induces a senescence-like phenotype in smooth muscle cells and promotes development of vascular degeneration
por: Zhang, Wenjing, et al.
Publicado: (2020)

Benefits of Curcumin in the Vasculature: A Therapeutic Candidate for Vascular Remodeling in Arterial Hypertension and Pulmonary Arterial Hypertension?
por: Li, Ke-Xue, et al.
Publicado: (2022)

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling
por: Dai, Zhiyu, et al.
Publicado: (2019)

Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells
por: Negi, Sandeep S., et al.
Publicado: (2015)

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
por: Hilton, John, et al.
Publicado: (2022)

Pulmonary Vascular Remodeling in Pulmonary Hypertension
por: Jia, Zhuangzhuang, et al.
Publicado: (2023)

Notch3 signalling and vascular remodelling in pulmonary arterial hypertension
por: Morris, Hannah E., et al.
Publicado: (2019)

Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients
por: Cui, Xiaopei, et al.
Publicado: (2022)

Glutaminolysis: A Driver of Vascular and Cardiac Remodeling in Pulmonary Arterial Hypertension
por: Mprah, Richard, et al.
Publicado: (2021)

Progenitor/Stem Cells in Vascular Remodeling during Pulmonary Arterial Hypertension
por: Dierick, France, et al.
Publicado: (2021)

Inhibition of microRNA-30a alleviates vascular remodeling in pulmonary arterial hypertension
por: Ma, Wenrui, et al.
Publicado: (2021)

TRB3 mediates vascular remodeling by activating the MAPK signaling pathway in hypoxic pulmonary hypertension
por: Cao, Xiaopei, et al.
Publicado: (2021)

A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer
por: Chung, Shin-Yi, et al.
Publicado: (2022)

Piezo1 in vascular remodeling of atherosclerosis and pulmonary arterial hypertension: A potential therapeutic target
por: Xu, Han, et al.
Publicado: (2022)

rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis
por: Negi, Sandeep S., et al.
Publicado: (2015)

Vascular Remodeling in Pulmonary Arterial Hypertension: The Potential Involvement of Innate and Adaptive Immunity
por: Tobal, Rachid, et al.
Publicado: (2021)

Characteristics of Pulmonary Vascular Remodeling in a Novel Model of Shunt-Associated Pulmonary Arterial Hypertension
por: Zhang, Mingjie, et al.
Publicado: (2018)

The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension
por: Wang, Yuhua, et al.
Publicado: (2019)

FUT8-Mediated Core Fucosylation Promotes the Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension
por: Zhang, Wen, et al.
Publicado: (2023)

mTORC1 in Pulmonary Arterial Hypertension. At the Crossroads between Vasoconstriction and Vascular Remodeling?
por: Goncharova, Elena A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_04k4gent83b32krg4h2u086a04